Cannabis Legalization and Public Health: What the Data Shows After a Decade
A data-driven review of what has — and has not — changed since recreational legalization began
More than a decade after Colorado and Washington became the first US states to legalize recreational cannabis, researchers have accumulated substantial data on the public health effects of legalization. The findings are more nuanced — and more mixed — than either advocates or opponents predicted.
Adolescent Use: The Most Watched Metric
One of the central predictions of legalization opponents was that making cannabis legal would increase adolescent use. The data, a decade in, is more reassuring than many expected. National survey data (Monitoring the Future, NSDUH) show that adolescent cannabis use has not significantly increased in states that legalized recreational cannabis compared to non-legalization states. A 2019 JAMA Pediatrics study found no significant increase in adolescent cannabis use following recreational legalization in 8 states.
However, the picture is not entirely positive. While overall adolescent use rates have not spiked, the potency of cannabis available to adolescents has increased dramatically — average THC content has risen from ~4% in the 1990s to 12–20%+ in current dispensary products. Adolescents who do use cannabis are therefore using substantially more potent products than previous generations, potentially increasing the risk of adverse outcomes even at similar use rates.
Adult Use: The Expected Increase
Adult cannabis use has increased significantly in states with recreational legalization — this was expected and has been confirmed. A 2020 JAMA Internal Medicine study found that recreational legalization was associated with a 25% increase in adult cannabis use. Daily or near-daily use — the pattern most associated with adverse health outcomes — increased by approximately 20%.
The increase in adult use has been concentrated in older adults (35+), a demographic with higher rates of cardiovascular disease and polypharmacy — groups for whom cannabis carries greater risks. The increase in cannabis use disorder diagnoses has tracked the increase in use, though the absolute rates remain lower than for alcohol or tobacco.
Opioid Overdose: A Complex Picture
The relationship between cannabis legalization and opioid overdose mortality has been one of the most debated topics in drug policy research. A landmark 2014 JAMA Internal Medicine study (Bachhuber et al.) found that states with medical cannabis laws had 24.8% lower opioid overdose mortality than states without. This finding generated enormous interest and was widely cited as evidence that cannabis could help address the opioid crisis.
However, subsequent research has complicated this picture. A 2019 PNAS study found that the association between medical cannabis laws and reduced opioid mortality disappeared — and reversed — when the analysis was extended to include data from 2010–2017, the period of the fentanyl-driven overdose surge. The authors concluded that the earlier finding reflected a spurious correlation rather than a causal effect. The relationship between cannabis access and opioid use remains an active and contested area of research.
Traffic Safety: A Genuine Concern
Traffic safety is one area where legalization has produced genuinely concerning data. Multiple studies have found increases in cannabis-involved traffic fatalities following recreational legalization. A 2020 study in the American Journal of Public Health found a 17% increase in traffic fatalities in states that legalized recreational cannabis compared to control states. A 2019 Insurance Institute for Highway Safety study found a 6% increase in injury crash rates in states with recreational dispensaries.
The mechanism is straightforward: cannabis impairs driving, and increased availability increases the likelihood of impaired driving. The challenge is that unlike alcohol, there is no reliable roadside test for cannabis impairment — blood THC levels are a poor proxy for impairment, and oral fluid tests detect past use rather than current impairment. Developing better impairment detection tools is a significant public health priority.
Mental Health: Emerging Concerns
The mental health effects of legalization are beginning to emerge in population-level data. A 2020 JAMA Psychiatry study found that recreational legalization was associated with a 25% increase in cannabis use disorder diagnoses. A 2021 study found increases in cannabis-associated psychosis hospitalizations in Colorado following legalization, concentrated in young adult males — the highest-risk demographic for cannabis-induced psychosis.
The increase in high-potency products available in legal markets is a particular concern. The association between high-potency cannabis (>10% THC) and psychosis risk is well-established in epidemiological research. Legal markets have not, in most jurisdictions, implemented potency caps or meaningful restrictions on high-THC products. Whether the mental health consequences of high-potency product availability will become a major public health issue in the coming decade is one of the most important unanswered questions in cannabis policy.
The Bottom Line: A Mixed Picture
After a decade of data, the public health effects of cannabis legalization are neither the catastrophe opponents predicted nor the unambiguous success advocates promised. Adolescent use has not spiked; tax revenue has been substantial; arrests for cannabis possession have plummeted. But adult use and cannabis use disorder have increased; traffic fatalities have risen in some analyses; and the mental health consequences of high-potency product proliferation are a growing concern.
The policy lesson may be that legalization's public health impact depends heavily on implementation details: potency regulations, marketing restrictions, age verification, public education, and investment of tax revenue in treatment and prevention. States that have treated legalization as a public health intervention — rather than purely a revenue opportunity — may achieve better outcomes than those that have not.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making treatment decisions. See our editorial standards.